Y Intercept Hong Kong Ltd Purchases Shares of 93,822 Haleon PLC Sponsored ADR $HLN

Y Intercept Hong Kong Ltd purchased a new position in Haleon PLC Sponsored ADR (NYSE:HLN) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 93,822 shares of the company’s stock, valued at approximately $939,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Morgan Stanley increased its position in shares of Haleon by 16.0% in the 4th quarter. Morgan Stanley now owns 21,495,383 shares of the company’s stock valued at $217,318,000 after acquiring an additional 2,962,856 shares during the period. Norges Bank acquired a new stake in Haleon during the 4th quarter worth about $163,529,000. Bank of America Corp DE grew its stake in Haleon by 116.7% during the 2nd quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after purchasing an additional 6,669,923 shares during the last quarter. Sculptor Capital LP increased its holdings in shares of Haleon by 5.1% in the fourth quarter. Sculptor Capital LP now owns 10,454,868 shares of the company’s stock valued at $105,699,000 after purchasing an additional 505,000 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in shares of Haleon by 18.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 10,441,178 shares of the company’s stock worth $105,560,000 after purchasing an additional 1,589,494 shares during the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Argus raised Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Rothschild & Co Redburn cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a report on Tuesday, June 30th. Finally, Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a research note on Sunday. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Haleon presently has an average rating of “Moderate Buy”.

Haleon Stock Performance

Shares of HLN stock opened at $9.77 on Monday. The company has a market capitalization of $43.04 billion, a P/E ratio of 25.04, a P/E/G ratio of 2.26 and a beta of 0.13. The business’s 50 day moving average is $9.20 and its two-hundred day moving average is $9.86. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 0.47. Haleon PLC Sponsored ADR has a 12-month low of $8.65 and a 12-month high of $11.28.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.